Vitaspring Biomedical Co. Ltd. (VSBC): Total Liabilities
$4.45M
As of 2026-01-31
$4.68M
As of 2026-07-31
+12.0%
3-year compound annual growth
+116.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-31 | $4.45M | +10.3% | 2026-06-17, Balance as of period end |
| 2025-01-31 | $4.03M | +15.5% | 2026-06-17, Balance as of period end |
| 2024-01-31 | $3.49M | +10.3% | 2026-06-08, Balance as of period end |
| 2023-01-31 | $3.16M | +56.1% | 2026-03-12, Balance as of period end |
| 2022-01-31 | $2.03M | n/m | 2025-12-01, Balance as of period end |
| 2021-01-31 | $93.0K | n/c | 2022-05-03, Balance as of period end |
| 2020-01-31 | $0 | -100.0% | 2021-04-14, Balance as of period end |
| 2019-01-31 | $11.4K | -11.3% | 2020-06-09, Balance as of period end |
| 2018-01-31 | $12.9K | +183.0% | 2019-04-26, Balance as of period end |
| 2017-01-31 | $4.6K | n/a | 2018-05-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vitaspring Biomedical Co. Ltd. (VSBC) | 2026-01-31 | $4.45M | +10.3% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.79B | -10.3% |
| Icon PLC (ICLR) | 2025-12-31 | $7.08B | -1.6% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $3.92B | -2.4% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $1.20M | +5.2% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $23.31B | +11.9% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.44M | +6.7% |
Compare VSBC, NRC, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗